Arbor Biotechnologies to Acquire Serendipity Biosciences

Share this
Arbor Biotechnologies


Arbor Biotechnologies to Acquire Serendipity Biosciences


  • Arbor Biotechnologies has agreed to acquire Serendipity Biosciences, enhancing its genomic medicines portfolio. Financial terms were undisclosed
  • The acquisition will add Serendipity’s editing assets incl. Fanzor-based, IsrB-based & additional undisclosed programmable editing technologies to Arbor’s portfolio. These nuclease technologies will expand the therapeutic applications of Arbor’s genomic medicines
  • Furthermore, these CRISPR-Cas-based technologies will strengthen Arbor’s RT editing and both RNA & DNA-based exon/entire gene insertion in vivo using cutting properties (natural nickases), expanded genomic targeting as well as smaller sizes for delivery via AAV vectors and other size-constrained vehicles

Ref: Arbor Biotechnologies | Image: Arbor Biotechnologies

Related News:- Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions